Multivariate analysis of Factors for Overall Survival according to the Selected Ki-67 cut-off points.

<p>Multivariate analysis of Factors for Overall Survival according to the Selected Ki-67 cut-off points.</p

Multivariate Analysis of Factors for Disease-free and Overall Survival in Primary Breast cancer.

<p>Multivariate Analysis of Factors for Disease-free and Overall Survival in Primary Breast cancer.</p

Overall survival based on the Ki-67 cut-off point of 20% according to breast cancer subtypes.

<p>(The OS rates of patients with lower Ki-67 values (<20%) was significantly higher than those with higher Ki-67 values (≥20%) in the luminal/HER2- subtype (A). However, there were no significant correlations between the Ki-67 cut-off point of 20% and survival in any of the other subtypes (B, C, D).)</p

Univariate analysis for Disease-Free and Overall Survival using Different Ki-67 cut-off points.

<p>Univariate analysis for Disease-Free and Overall Survival using Different Ki-67 cut-off points.</p

BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer

<div><p>Background</p><p>Triple-negative breast cancer (TNBC) is a heterogeneous tumor that encompasses many different subclasses of the disease. In this study, we assessed BRCAness, defined as the shared characteristics between sporadic and <i>BRCA1</i>-mutated tumors, in a large cohort of TNBC cases.</p><p>Methods</p><p>The BRCAness of 262 patients with primary TNBCs resected between January 2004 and December 2014 was determined through the isolation of DNA from tumor tissue. Classification of BRCAness was performed using multiple ligation-dependent probe amplification (MLPA). The tumor subtypes were determined immunohistochemically using resected specimens.</p><p>Results</p><p>Of the 262 TNBCs, the results of the MLPA assays showed that 174 (66.4%) tumors had BRCAness. Patients with BRCAness tumors were younger than patients with non-BRCAness tumors (<i>P</i> = 0.003). There was no significant difference between the two groups regarding their pathological stages. The BRCAness group had a significantly shorter recurrence-free survival (RFS) compared with the non-BRCAness group (<i>P</i> = 0.04) and had a shorter overall survival (OS) although this did not reach statistical significance. Adjuvant treatments with anthracycline-based regimens provided significantly greater benefits to the BRCAness group (<i>P</i> = 0.003 for RFS, and <i>P</i> = 0.03 for OS). Multivariate Cox proportional hazard model analysis showed that BRCAness was an independent negative prognostic factor, and the anthracycline-based adjuvant chemotherapy was an independent positive prognostic factor for both RFS and OS in TNBC.</p><p>Conclusions</p><p>The 66.4% patients of TNBCs showed BRCAness. BRCAness is essential as a biomarker in the subclassification of TNBCs and might be of use for predicting their prognosis. Furthermore, this biomarker might be a predictive factor for the effectiveness of anthracycline-based adjuvant chemotherapy for patients with TNBCs.</p></div

Patients and tumor characteristics (<i>n</i> = 262).

<p>Patients and tumor characteristics (<i>n</i> = 262).</p

Kaplan–Meier analysis of patients who received anthracycline-based adjuvant chemotherapy versus non-anthracycline-based adjuvant chemotherapy.

<p>(A) Recurrence-free survival (RFS) of BRCAness tumors (<i>n</i> = 126). (B) Overall survival (OS) of BRCAness tumors (<i>n</i> = 126). (C) RFS of non-BRCAness tumors (<i>n</i> = 53). (D) OS of non-BRCAness tumors (<i>n</i> = 53). Anthracycline or Anthra, anthracycline-based adjuvant chemotherapy; Non-Anthracycline or Non-Anthra, non-anthracycline-based adjuvant chemotherapy.</p

Cox proportional hazards model for recurrence-free survival and overall survival (<i>n</i> = 262).

<p>Cox proportional hazards model for recurrence-free survival and overall survival (<i>n</i> = 262).</p

Kaplan–Meier analysis of patients with TNBC (<i>n</i> = 262).

<p>(A) Recurrence-free survival of BRCAness tumors versus non-BRCAness tumors. (B) Overall survival of BRCAness tumors versus non-BRCAness tumors.</p